UCL study reveals carbon beads could help reduce progression of liver disease
Liver cirrhosis, caused by long-term liver damage, is estimated to affect around 100 million people worldwide
Read More
Tag: liver disease
Albireo submits rare liver disease med odevixibat to FDA and EMA
If approved, drug will become first treatment for PFIC patients in the US and EU
Read More
Owlstone Medical’s breath biopsy test improves detection of liver disease
Study detected Nonalcoholic Fatty Liver Disease and Nonalcoholic steatohepatitis
Read More
US committee backs terlipressin approval for HRS-1
HRS-1 is an acute and life-threatening syndrome with a survival time of just two weeks if left untreated
Read More
NICE pushes Doptelet for pre-surgery liver disease treatment
Last year, the therapy received a positive opinion from the EMA’s CHMP.
Read More
FDA warning on Intercept’s Ocaliva after patient deaths
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Read More
Novartis scoops up rights to NASH drug
Novartis has exercised an option giving it global development and commercialisation rights to an experimental drug being developed by US biotech Conatus for nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.
Read More
BMS presents promising data for NASH drug
Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).
Read More
NICE backs new treatment for chronic liver disease
Intercept’s Ocaliva is being backed by the National Institute for Health and Care Excellence for routine NHS commissioning as a treatment for people with the chronic liver disease primary biliary cholangitis (PBC).
Read More
EU approves new therapy for rare liver condition PBC
The European Commission has cleared Intercept’s Ocaliva for the treatment of primary biliary cholangitis (PBC), giving patients the potential to access the first new therapy for the condition in nearly 20 years.
Read More
- US study reveals interferon combinations cause lupus symptoms and affect treatment
- NIHR and TJBCM announce new funding initiative for novel brain tumour research
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
